Frailty, Hip Fractures and Inflammatory Biomarkers
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age65+
SponsorUniversity of Thessaly
About this trial
We ought to investigate if hip fracture patients suffering from frailty have higher inflammatory burden according to simple inflammatory biomarkers.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
age >65 years, ASA PS I-III, non- institutionalized, able to communicate patients
Disqualifiers
Patients with severe cognitive dysfunction, those treated conservatively, those with pathological fractures and patients who refused to participate
Trial population
hip fracture patients treated with surgery
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
200 Participants
are grouped into 1 trial groupGroup A: hip fracture patients treated with surgery
Trial outcomes
Primary outcomes
1
Frailty status
Frailty will be categorized based on the validated Groningen Frailty Indicator (GFI) as non-frail (NF, score 0,1), pre-frail (PF, score 2, 3) and severe frail (SF, score \>4).
Time frame
preoperatively2
Inflammatory biomarkers
Upon admission and immediate before surgery upper limits of white blood cells (WBC) within normal range (WBC \>8 10\^3/μL), NLR (neutrophils/lymphocytes), PLR (platelets/lymphocytes), CRP (C-reactive protein) and CLR (CRP/lymphocytes), will be recorded.
Time frame
preoperativelySponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov